Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) With Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing
Latest Information Update: 26 Oct 2022
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics; Pharmacogenomic
- 20 Oct 2022 Status changed from active, no longer recruiting to completed.
- 01 Jul 2021 Results of pooled analysis of data from NCT01942837 and NCT02025010 studies to evaluate the clinical outcomes using a multiplex liquid biopsy targeting diverse resistance mechanisms in metastatic Prostate cancer published in the Journal of Clinical Oncology
- 13 Apr 2021 Results published in the Clinical Cancer Research